May 17, 2021
Astellas Pharma said on May 14 that the Japanese health ministry has granted priority review status to its investigational antibody-drug conjugate (ADC) enfortumab vedotin, which is developed with its US partner Seagen. The compound is currently under regulatory review for...read more